Intestinal Diffuse Large B-Cell Lymphoma: An Evaluation of Different Staging Systems

• DOI: 10.3346/jkms.2014.29.1.53
• Publication Date: 2014-01-03T10:37:28Z
• Authors: Hee Sang Hwang; Dok Hyun Yoon; Cheolwon Suh; Chan-Sik Park; Jooryung Huh
• Keywords: Univariate analysis; Regimen; Prednisolone

The gastrointestinal tract is the most common primary extranodal site for diffuse large B-cell lymphoma (DLBCL).However, there no consensus on appropriate staging system intestinal DLBCL.We evaluated utility of modified Ann Arbor system, Lugano and Paris (a modification Tumor, Node, Metastases [TNM] epithelial tumors) in 66 cases resected DLBCL.The were treated with surgery, plus either cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) chemotherapy alone (n = 26) or addition rituximab immunotherapy 40).Median follow-up time was 40.4 months (range, 2.1-171.6months).Fifty-six patients (84.8%) achieved complete remission.The overall 5-yr survival rate 86.4% (57/66).Of stage categories defined each only T classification showed prognostic significance by univariate analysis.However, none parameters significantly correlated patient multivariate analysis.In conclusion, results suggest that may be a indicator also imply surgically DLBCL, to CHOP regimen does not confer significant advantage.